Mollugin
Catalog No: CFN98930
Mollugin is a JAK2 inhibitor and inhibits LPS-induced inflammatory responses by blocking the activation of the JAK-STAT pathway. Mollugin may be a novel therapeutic candidate for bone loss-associated disorders including osteoporosis, rheumatoid arthritis, and periodontitis. Mollugin has anticancer efficacy, can modulate the HER2, HO-1, Nrf2 , and NF- κB pathways.
Rubiadin 1-methyl ether
Catalog No: CFN97227
Rubiadin-1-methyl ether probed as Type I photosensitizers. Rubiadin 1-methyl ether decreases the number of parasites (schizonts) in a dose-dependent manner, and 100% of inhibition was obtained with 30 to 40 micrograms. Rubiadin-1-methyl ether shows strong enhancing activity for adipocyte differentiation, it could be beneficial in the treatment of diabetes. Rubiadin-1-methyl ether has therapeutic potential against osteoporosis, it can promote osteoblast proliferation and inhibit osteoclast TRAP activity and bone resorption, and the inhibitory effects on osteoclastic bone, antiosteoporotic activity of M. officinalis .
Diosmetin
Catalog No: CFN90210
Diosmetin has anti-osteoporosis, cytoprotective, antibacterial, anti-pigmentation, anti-inflammatory and antioxidant properties, it induces osteoblastic differentiation through the PKCδ-Rac1-MEK3/6-p38 and PKCδ-Rac1-MEK1/2- ERK1/2-Runx2 pathways.Diosmetin has intracellular antioxidant detoxifying effect, the mechanism is associated with both nonenzymatic and enzymatic defense systems.Diosmetin and luteolin exert synergistic cytostatic effects in human hepatoma HepG2 cells via CYP1A-catalyzed metabolism, activation of JNK and ERK and P53/P21 up-regulation.